ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RES

/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and...

Related Keywords

New York , United States , California , Canada , Dublin , Ireland , Chestnut Ridge , Irvine , Canadian , Blaise Coleman , Company Net , Branded Pharmaceuticals , Company Net Debt Leverage Ratio , Linkedin , Generic Pharmaceuticals , Endo Investor Relations Department , Nasdaq , Exchange Commission , International Pharmaceuticals , Pfizer Inc , Endo International , Company Loss , Chief Executive Officer , Months Ended December , Ended December , Diluted Net , Continuing Operations , Diluted Weighted Average Shares , Diluted Net Income , Adjusted Diluted Weighted Average Shares , Adjusted Income , Sterile Injectables , Specialty Products , Note Regarding Forward Looking Statements , Operating Expenses , Total Revenues , Nasal Spray , Condensed Consolidated Statement , Condensed Consolidated Balance Sheet , Cash Flow , Qualified Settlement , Current Report , Supplemental Financial Information , Consolidated Statements , Net Debt Leverage Ratio , Net Debt , Restricted Cash , Net Debt Leverage , Debt Leverage Ratio , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Endo International Plc ,